Table 1.
Clinical characteristics according to regdanvimab usage.
| Users (n = 89) | Non-Users (n = 63) | p-Value | |
|---|---|---|---|
| Age | 46.9 (43.9–49.8) | 36.1 (32.9–39.3) | <0.001 |
| Men | 44 (49.4) | 33 (52.4) | 0.721 |
| BMI | 27.0 (25.9–28.2) | 25.3 (24.0–26.7) | 0.063 |
| PCR result (Ct value) | |||
| RdRp | 17.8 (16.54–19.06) | 18.31 (16.79–19.82) | 0.611 |
| Envelope (E) gene | 19.05 (17.83–20.23) | 19.12 (17.53–20.7) | 0.946 |
| Nucleocapsid (N) gene | 16.12 (14.29–17.95) | 16.69 (14.65–18.73) | 0.679 |
| Charlson comorbidity index | 0.9 (0.67–1.13) | 0.3 (0.12–0.48) | <0.001 |
| Vaccine completion | 0.008 | ||
| No | 67 (75.3) | 58 (92.1) | |
| Yes | 22 (24.7) | 5 (7.9) | |
| Smoking | 0.643 | ||
| Never | 61 (68.5) | 43 (68.3) | |
| Former | 4 (4.5) | 5 (7.9) | |
| Current | 24 (27.0) | 15 (23.8) | |
| Initial vital sign | |||
| Systolic BP | 124.4 (121.3–127.4) | 121.3 (118.3–124.4) | 0.267 |
| Diastolic BP | 81.7 (79.6–83.7) | 80.6 (78.1–83) | 0.475 |
| Heart rate | 82 (79–85) | 80 (77–83) | 0.476 |
| Respiratory rate | 16.1 (15.7–16.5) | 16 (15.6-16.4) | 0.835 |
| Body temperature | 37.9 (37.7–38.1) | 37.4 (37.3–37.6) | <0.001 |
| Length of admission | 9.5 (9.2–9.9) | 9.1 (8.8–9.4) | 0.111 |
| Transfer-out or death | 2 (2.2) | 0 (0) | 0.511 |
| Pneumonia at admission | 58 (65.2) | 15 (23.8) | <0.001 |
| Remdesivir use | 23 (25.8) | 14 (22.2) | 0.608 |
| Dexamethasone use | 9 (10.1) | 7 (11.1) | 0.843 |
| Oxygen supplement | 12 (13.5) | 9 (14.3) | 0.888 |
Data are presented as mean and 95% confidence interval for continuous variables and numbers and percentages for categorical variables, otherwise stated. For continuous variables with normal distribution, a t-test was performed, and for variables that violated the normality, a Wilcoxon rank-sum test was performed (SBP, DBP, and HR). BMI = body mass index; PCR = polymerase chain reaction; Ct = cycle threshold; RdRp = RNA-dependent RNA polymerase; BP = blood pressure.